Artificial intelligence research in the COVend COVID-19 clinical trial project

Alpo Olavi Värri; Antti Kallonen; Tunc Asuroglu; Mark van Gils

doi:10.23996/fjhw.126881

Artificial intelligence research in the COVend COVID-19 clinical trial project

Alpo Olavi Värri, Antti Kallonen, Tunc Asuroglu, Mark van Gils

Research output: Contribution to journal › Article › Scientific

5 Downloads (Pure)

Abstract

The COVend project aims at delivering a new effective therapy, FX06, against the SARS-CoV-2 virus infection for the management of the COVID-19 disease in hospitals. Nine of the 17 partners of the project consortium are hospitals responsible for collecting study subjects and administering the FX06 therapy to the patients. Although the clinical trial (IXION) has the main role in the project, the project has also a work package which develops and applies artificial intelligence (AI) methods to the data collected during the 28-day study period from the patients receiving the therapy. The AI work package applies exploratory data analysis methods to find patterns and profiles of the patients. Combined with the data about treatment methods and patient outcomes, the aim is to provide decision support for the therapy intervention in the later stage of the project.

Original language	English
Pages (from-to)	230-234
Number of pages	5
Journal	Finnish Journal of eHealth and eWelfare
Volume	15
Issue number	2
DOIs	https://doi.org/10.23996/fjhw.126881
Publication status	Published - 20 Apr 2023
Publication type	B1 Journal article

Access to Document

10.23996/fjhw.126881Licence: CC BY

126881-Article Text-276559-1-10-20230418Final published version, 213 KBLicence: CC BY

https://urn.fi/URN:NBN:fi:tuni-202306016380Licence: CC BY

Cite this

@article{e025d38e468c4b26963f5cfe7e8cb300,

title = "Artificial intelligence research in the COVend COVID-19 clinical trial project",

abstract = "The COVend project aims at delivering a new effective therapy, FX06, against the SARS-CoV-2 virus infection for the management of the COVID-19 disease in hospitals. Nine of the 17 partners of the project consortium are hospitals responsible for collecting study subjects and administering the FX06 therapy to the patients. Although the clinical trial (IXION) has the main role in the project, the project has also a work package which develops and applies artificial intelligence (AI) methods to the data collected during the 28-day study period from the patients receiving the therapy. The AI work package applies exploratory data analysis methods to find patterns and profiles of the patients. Combined with the data about treatment methods and patient outcomes, the aim is to provide decision support for the therapy intervention in the later stage of the project.",

author = "V{\"a}rri, {Alpo Olavi} and Antti Kallonen and Tunc Asuroglu and {van Gils}, Mark",

year = "2023",

month = apr,

day = "20",

doi = "10.23996/fjhw.126881",

language = "English",

volume = "15",

pages = "230--234",

journal = "Finnish Journal of eHealth and eWelfare",

issn = "1798-0798",

publisher = "Sosiaali- ja terveydenhuollon tietojenk{\"a}sittely-yhdistys ry",

number = "2",

}

TY - JOUR

T1 - Artificial intelligence research in the COVend COVID-19 clinical trial project

AU - Värri, Alpo Olavi

AU - Kallonen, Antti

AU - Asuroglu, Tunc

AU - van Gils, Mark

PY - 2023/4/20

Y1 - 2023/4/20

N2 - The COVend project aims at delivering a new effective therapy, FX06, against the SARS-CoV-2 virus infection for the management of the COVID-19 disease in hospitals. Nine of the 17 partners of the project consortium are hospitals responsible for collecting study subjects and administering the FX06 therapy to the patients. Although the clinical trial (IXION) has the main role in the project, the project has also a work package which develops and applies artificial intelligence (AI) methods to the data collected during the 28-day study period from the patients receiving the therapy. The AI work package applies exploratory data analysis methods to find patterns and profiles of the patients. Combined with the data about treatment methods and patient outcomes, the aim is to provide decision support for the therapy intervention in the later stage of the project.

AB - The COVend project aims at delivering a new effective therapy, FX06, against the SARS-CoV-2 virus infection for the management of the COVID-19 disease in hospitals. Nine of the 17 partners of the project consortium are hospitals responsible for collecting study subjects and administering the FX06 therapy to the patients. Although the clinical trial (IXION) has the main role in the project, the project has also a work package which develops and applies artificial intelligence (AI) methods to the data collected during the 28-day study period from the patients receiving the therapy. The AI work package applies exploratory data analysis methods to find patterns and profiles of the patients. Combined with the data about treatment methods and patient outcomes, the aim is to provide decision support for the therapy intervention in the later stage of the project.

U2 - 10.23996/fjhw.126881

DO - 10.23996/fjhw.126881

M3 - Article

SN - 1798-0798

VL - 15

SP - 230

EP - 234

JO - Finnish Journal of eHealth and eWelfare

JF - Finnish Journal of eHealth and eWelfare

IS - 2

ER -

Artificial intelligence research in the COVend COVID-19 clinical trial project

Abstract

Access to Document

Fingerprint

Cite this